Silk Road Medical, Inc (NASDAQ:SILK) Given Average Rating of "Hold" by Brokerages

Shares of Silk Road Medical, Inc (NASDAQ:SILK - Get Free Report) have been given a consensus rating of "Hold" by the eleven brokerages that are currently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $22.55.

Several equities analysts have recently issued reports on the company. JPMorgan Chase & Co. increased their price target on shares of Silk Road Medical from $19.00 to $21.00 and gave the stock a "neutral" rating in a report on Wednesday, May 1st. Argus upgraded Silk Road Medical from a "hold" rating to a "buy" rating and set a $24.00 target price on the stock in a research report on Thursday, March 7th. Stifel Nicolaus upped their price target on Silk Road Medical from $20.00 to $23.00 and gave the stock a "buy" rating in a report on Thursday, February 29th. Finally, Piper Sandler raised their price objective on Silk Road Medical from $18.00 to $20.00 and gave the company a "neutral" rating in a report on Wednesday, May 1st.

Insider Transactions at Silk Road Medical

In other Silk Road Medical news, insider Andrew S. Davis sold 5,481 shares of the stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $17.17, for a total transaction of $94,108.77. Following the sale, the insider now directly owns 287,773 shares in the company, valued at approximately $4,941,062.41. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Silk Road Medical news, insider Andrew S. Davis sold 5,481 shares of the company's stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $17.17, for a total transaction of $94,108.77. Following the sale, the insider now owns 287,773 shares in the company, valued at approximately $4,941,062.41. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Kevin J. Ballinger purchased 11,700 shares of Silk Road Medical stock in a transaction on Tuesday, March 5th. The stock was bought at an average cost of $16.99 per share, for a total transaction of $198,783.00. Following the transaction, the director now directly owns 17,807 shares in the company, valued at $302,540.93. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 20,457 shares of company stock valued at $351,247. 6.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Silk Road Medical

Hedge funds and other institutional investors have recently made changes to their positions in the business. Swiss National Bank lifted its stake in Silk Road Medical by 1.7% in the third quarter. Swiss National Bank now owns 85,200 shares of the company's stock valued at $1,277,000 after buying an additional 1,400 shares during the last quarter. CWM LLC raised its position in Silk Road Medical by 151.5% in the 4th quarter. CWM LLC now owns 2,563 shares of the company's stock valued at $31,000 after purchasing an additional 1,544 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Silk Road Medical by 28.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,295 shares of the company's stock worth $139,000 after purchasing an additional 2,049 shares during the period. RiverPark Advisors LLC purchased a new position in Silk Road Medical during the 3rd quarter worth $34,000. Finally, PNC Financial Services Group Inc. increased its stake in Silk Road Medical by 1,293.9% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,523 shares of the company's stock valued at $31,000 after purchasing an additional 2,342 shares during the period.

Silk Road Medical Stock Down 1.6 %

SILK traded down $0.34 on Tuesday, hitting $20.56. The company had a trading volume of 518,550 shares, compared to its average volume of 786,179. Silk Road Medical has a 12-month low of $6.08 and a 12-month high of $43.51. The company has a debt-to-equity ratio of 0.50, a current ratio of 7.95 and a quick ratio of 6.97. The stock has a fifty day moving average price of $17.80 and a 200-day moving average price of $13.80.

Silk Road Medical (NASDAQ:SILK - Get Free Report) last released its earnings results on Tuesday, April 30th. The company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.40) by $0.04. Silk Road Medical had a negative net margin of 29.02% and a negative return on equity of 35.12%. The company had revenue of $48.50 million during the quarter, compared to analysts' expectations of $44.67 million. During the same period last year, the business earned ($0.43) EPS. Silk Road Medical's revenue for the quarter was up 20.9% on a year-over-year basis. On average, equities research analysts forecast that Silk Road Medical will post -1.43 EPS for the current year.

About Silk Road Medical

Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure.